Celldex Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Leadership changes affect company direction; investors watch for successor stability and management continuity.
More shares available dilutes existing ownership but helps attract and retain talented employees.
Quarterly earnings show company progress; helps investors understand if the business is growing or shrinking.
Company raises cash for operations and growth; new shares dilute ownership but fund future development.
Legal document enabling the company to sell new shares; signals planned fundraising to investors.
Formal deal to sell 10.3 million shares; shows major banks backing the company's stock offering.
Legal filing allows company to raise money by selling stock; demonstrates capital-raising plans.
Stocky reads Celldex Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Celldex Therapeutics, Inc.'s most recent tracked filing was a 8-K on 15 Jul 2026: CFO Sam Martin plans retirement effective March 31, 2027.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.